Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Lexaria Bioscience raised $4M via a stock offering to fund operations, with shares priced at $1.50 and warrants at $1.37.
Lexaria Bioscience Corp. (LEXX:NASDAQ) announced a $4.0 million registered direct offering of 2,666,667 shares at $1.50 per share, priced at-the-market under Nasdaq rules, with closing expected around September 29, 2025, subject to customary conditions.
A concurrent private placement includes unregistered warrants to purchase up to the same number of shares at $1.37 per share, exercisable immediately and expiring in five years.
Proceeds, before expenses, are expected to be about $4.0 million for working capital and general corporate purposes.
The offering is under a shelf registration statement on Form S-3, effective January 30, 2025.
The company’s DehydraTECH™ platform aims to improve oral drug delivery, including across the blood-brain barrier, and it holds 50 granted patents and additional pending applications globally.
Forward-looking statements involve risks and uncertainties.
Lexaria Bioscience recaudó $ 4M a través de una oferta de acciones para financiar operaciones, con acciones a un precio de $ 1.50 y warrants a $ 1.37.